Search Results
You are looking at 1 - 5 of 5 items for
- Author: A. F. Bristow x
- Refine by access: All content x
Search for other papers by R. E. Gaines Das in
Google Scholar
PubMed
Search for other papers by A. F. Bristow in
Google Scholar
PubMed
ABSTRACT
Four batches of ampouled materials in ampoules coded 80/558, 81/502, 81/565 and 81/615 were evaluated by 22 laboratories in nine countries in an international collaborative study for their suitability to serve as a replacement for the First International Reference Preparation (IRP) of TSH, Human, for Immunoassay. The ampouled preparations were calibrated by immunoassay and bioassay. The preparation coded 80/558 had satisfactory stability and contained acceptably low levels of contamination with FSH and LH. Estimates of the immunoreactive TSH content of a set of specimens of serum in terms of 80/558 showed agreement in ranking order and no increase in variability compared with estimates made by assay against the First IRP. On the basis of these results, with the agreement of the participants in the study, and with the authorization of the Expert Committee on Biological Standardization of the World Health Organization, the preparation coded 80/558 was established in 1983 as the Second International Reference Preparation of TSH, Human, for Immunoassay, with a defined potency of 37 mi.u./ampoule. Preparations coded 81/502, 81/565 and 81/615 were found suitable to serve as working standards.
J. Endocr. (1985) 104, 367–379
Search for other papers by A. F. Bristow in
Google Scholar
PubMed
Search for other papers by R. P. Gooding in
Google Scholar
PubMed
Search for other papers by R. E. Gaines Das in
Google Scholar
PubMed
ABSTRACT
Three preparations of recombinant DNA-derived insulin-like growth factor-I (IGF-I) were obtained, prepared in ampoules coded 86/522, 86/720 or 87/518, and evaluated as candidate International Reference Reagents in an international collaborative study (nine laboratories in four countries) in response to a request by the World Health Organization (WHO).
Immunoassay dose–response curves for each of the three preparations did not in general differ significantly from those of local standards or from those of ampouled preparations of serum-derived IGF-I which were included in the study. The estimates of ampoule contents in terms of local standards showed considerable heterogeneity; the between-laboratory variability of estimates in terms of local standards was ten times greater than the inherent variability of estimates from these systems as estimated from comparisons of coded duplicates. Bioassay data were limited, and those available were inconsistent with immunoassay data. Of the three preparations, ampoules coded 86/720 were derived from an IGF-I preparation that was heterogeneous by high-performance liquid chromatography, and stability data for the preparation 86/522 were anomalous.
As a result, the ampouled preparation coded 87/518 has been established by WHO as the International Reference Reagent for IGF-I for immunoassay, with an assigned ampoule content of 3·1 μg/ampoule, and is available from the National Institute for Biological Standards and Control.
Journal of Endocrinology (1990) 125, 191–197
Search for other papers by P. M. Hagan in
Google Scholar
PubMed
Search for other papers by S. Poole in
Google Scholar
PubMed
Search for other papers by A. F. Bristow in
Google Scholar
PubMed
ABSTRACT
The acute-phase response involves a number of separate physiological components, including induction of acute-phase protein synthesis by the liver. This response can be induced in vivo by administration of the endogenous leucocytic mediator interleukin-1β. A number of in-vivo effects of interleukin-1β have been reported to be mediated by corticotrophin-releasing factor (CRF), including activation of the hypothalamo-pituitary-adrenal axis and induction of fever, and in this report we have examined a possible involvement of CRF in mediating interleukin-1β-induced acute-phase protein synthesis.
Interleukin-1β stimulated the elevation of species-specific plasma acute-phase proteins in rats, mice and rabbits. Co-injection of interleukin-1β with the specific CRF receptor antagonist α-helical-CRF9–41 NH2 abolished or attenuated acute-phase protein synthesis induced by interleukin-1β in all three species for up to 12 h after injection. The inhibitory effect of α-helical-CRF9–41NH2 was reduced or absent 24 h after injection. Neutralizing anti-CRF antisera had no effect on acute-phase protein synthesis in the mouse and, paradoxically, potentiated acute-phase protein synthesis induced by interleukin-1β in the rat. These results indicate a possible mediatory role for CRF in regulation of acute-phase protein synthesis, and suggest that CRF may mediate induction of acute-phase protein synthesis by a different mechanism from that involved in regulation of corticotrophin secretion.
Journal of Endocrinology (1993) 136, 207–216
Search for other papers by A. F. BRISTOW in
Google Scholar
PubMed
Search for other papers by D. MONTAGUE in
Google Scholar
PubMed
Search for other papers by D. SYNETOS in
Google Scholar
PubMed
Search for other papers by G. JENKINS in
Google Scholar
PubMed
Search for other papers by D. COCKAYNE in
Google Scholar
PubMed
Search for other papers by D. SCHULSTER in
Google Scholar
PubMed
In most previous reports material with corticotrophin releasing factor (CRF) activity has been obtained from hypothalami after extraction with dilute aqueous acid. Such conditions allow substantial proteolytic degradation. By adopting conditions designed to precipitate proteases and by using information on the nature of CRF gained from earlier studies, rapid large scale extraction and partial purification of porcine hypothalamic CRF in high yield was achieved. After extraction with 0·2 m-HCl: acetone (1: 1, v/v), centrifugation and ultrafiltration, considerable preliminary purification of the CRF activity was achieved by adsorption onto carboxymethylcellulose and subsequent elution at increased salt concentration. Following ion-exchange chromatography of the extract on carboxymethylcellulose, CRF activity was obtained in good yield (minimal effective dose of about 1–2 μg/ml) for ACTH release in an in-vitro CRF bioassay utilizing a coupled isolated pituitary cell–adrenal cell system. The data indicated that the previously reported heterogeneous corticotrophin releasing factors of low activity may be a consequence of proteolytic degradation.
Search for other papers by E A Linton in
Google Scholar
PubMed
Search for other papers by A V Perkins in
Google Scholar
PubMed
Search for other papers by P Hagan in
Google Scholar
PubMed
Search for other papers by S Poole in
Google Scholar
PubMed
Search for other papers by A F Bristow in
Google Scholar
PubMed
Search for other papers by F Tilders in
Google Scholar
PubMed
Search for other papers by R Corder in
Google Scholar
PubMed
Search for other papers by C D A Wolfe in
Google Scholar
PubMed
Abstract
Direct immunoassay of plasma corticotrophin-releasing hormone (CRH) is potentially subject to interference from high levels of CRH-binding protein (CRH-BP) that exist in the human circulation. In this study, we tested the effect of CRH-free, native CRH-BP (6·4 nmol/l) purified from human plasma, CRH-BP diluent alone, normal human plasma (containing 5·8 nmol endogenous CRH-BP/1) and normal sheep plasma (containing no CRH-BP) on the binding of 125I-labelled CRH tracer to five N-terminal and four C-terminal CRH antibodies. All anti-(1–20)CRH N-terminal antibody dilution curves displayed marked inhibition of binding in the presence of purified CRH-BP and human plasma in comparison with the curves with the control diluent or sheep plasma. Almost no inhibition of binding was obtained with any of the C-terminal antibodies (all directed against epitopes within the last six amino acids of CRH) and the four dilution curves were nearly superimposable. Liquid-phase CRH IRMAs were then developed with different combinations of two of each of the N- and C-terminal antibodies, using radiolabelled IgG prepared from purified C-terminal antisera as tracer and raw N-terminal antisera as the link antibodies to the separating system. The addition of dilutions of purified CRH-BP over the range 1·25–20 nmol/l to the IRMA standard curve in assay buffer resulted in a dose-dependent reduction in the signal; with 5 nmol CRH-BP/1, a level commonly found in human plasma, the reduction in binding was 67% and 81% in two different IRMAs at a CRH concentration of 631 pmol/l. With endogenous CRH-BP in human plasma, a dose-dependent inhibition of binding similarly resulted, with the plasma containing the most CRH-BP causing the greatest inhibition. Since plasma CRH-BP levels in humans vary widely, direct plasma IRMA using these type of antibodies will give inaccurate results and initial extraction of the CRH is necessary. Methanol extraction of synthetic or endogenous CRH is shown to be both highly efficient and unaffected by variable amounts of endogenous or exogenous CRH-BP; it is therefore suitable as the first step in plasma CRH measurement by IRMA.
Journal of Endocrinology (1995) 146, 45–53